TerminatedPhase 2NCT03165721

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
John W Glod, M.D.
National Cancer Institute (NCI)
Intervention
SGI-110 (guadecitabine)(drug)
Enrollment
9 enrolled
Eligibility
12-99 years · All sexes
Timeline
20172020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03165721 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials